Tender Details
Ref No 23816059
Document

Tender Notice

Bidding

Not specified

Short Description

Linezolid Solution For Infusions, 2 Mg/Ml In 300 Ml; Imipenem/Celastatin 500Mg/500Mg Powder For Solution For Infusions; Doxycycline 100 Mg Capsules/Tablets; Ofloxacin, Solution For Infusions, 2 Mg/Ml, 100 Ml Each; Piperacillin/Tazobactam, Powder (Lyophilisate) For Solution, 4 G/0.5 G Each. (Mnn: Linezolid, Ath: J01Xx08; Mnn: Imipenem And Cilastatin, Ath: J01Dh51; Mnn: Doxycycline, Ath: J01Aa02; Mnn: Ofloxacin, Ath: J01Ma01; Mnn: Piperacillin And Beta-Lactamase Inhibitor, Ath: J01Cr05). (Nomencla
Deadline *
Date 24 Jan 2026
* The estimated cost, values & dates are indicative only. Please read tender document for accurate information.
Client Address
Location Ukraine
More Information
Know More

FREE Trial Plan For All New Users!

Start your Business.

Similar Tenders

  • Ref No: 8259327
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Cre 2 5 Mg N1

  • Deadline: 10 May 2026
  • Ref No: 8260726
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Tab 10 Mg

  • Deadline: 10 May 2026
  • Ref No: 5310892
  • Location: Germany

Drug Contracts With An Option To Join

  • Deadline: 01 May 2026
  • Ref No: 5301821
  • Location: Bulgaria

Delivery Of Medicinal Products Which Are Included In Appendix 2 Of The Pds For The Needs Of Umbal Kanev Ad

  • Deadline: 27 May 2027
  • Ref No: 5396790
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient L

  • Deadline: 27 Apr 2026
  • Ref No: 5226107
  • Location: Germany

Medicines With The Active Ingredient Combination Vilanterol Umeclidinium Bromide And Fluticasone Furoate Atc R03Al08

  • Deadline: 31 Mar 2026
  • Ref No: 5976401
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Baclofen In The Dosage Form Inf

  • Deadline: 10 May 2026
  • Ref No: 5965319
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acetylcysteine As An Otc Medi

  • Deadline: 10 May 2026
  • Ref No: 5968352
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acetylcysteine In The Dosage

  • Deadline: 10 May 2026
  • Ref No: 8271966
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ciprofloxacin Oht Atr

  • Deadline: 10 May 2026
  • Ref No: 8280171
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Prednisolone Atr

  • Deadline: 10 May 2026
  • Ref No: 8281472
  • Location: Denmark

Qualification Scheme Technical Advice

  • Deadline: 28 Aug 2034
  • Ref No: 8296308
  • Location: Bulgaria

Sdp Supply Of Medicinal Products

  • Deadline: 31 Aug 2027
  • Ref No: 5714435
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 30 Apr 2026
WhatsApp Chat